Combination of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient: added value to brain tumour imaging and clinical feasibility of non-contrast MRI at 3 T.
The purpose of this study was to determine the benefit of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient for brain tumour imaging, and to assess the clinical feasibility of using a non-contrast MR protocol at 3 T. 73 patients with intra-axial tumours were enrolled into the study. Two experienced neuroradiologists reviewed three MRI sessions: (i) a non-contrast protocol including high-resolution susceptibility-weighted images and apparent diffusion coefficient; (ii) a contrast protocol including MR perfusion images; and (iii) combined contrast and non-contrast protocols. The two observers categorised tumours as glial or non-glial tumours, and then subcategorised the gliomas into low-grade or high-grade tumours. For semi-quantitative analysis, a scoring system based on the degree of intra-tumoral susceptibility signals and the visual apparent diffusion coefficient was used. The two observers diagnosed accurate tumour pathology in 52 (71%) of 73 tumours in the first review, 55 (75%) of 73 tumours in the second review and 61 (84%) of 73 tumours in the third review. The addition of the non-contrast protocol to the contrast protocol significantly differentiated glioblastoma multiforme and metastatic tumours, which was not possible with the contrast protocol alone. The sensitivity, specificity, positive predictive value and negative predictive value for glioma grading with the non-contrast protocol were 83.2%, 100%, 100% and 79.3%, respectively. The addition of both high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient improved the diagnostic performance of the contrast MR protocol for brain tumour imaging and could be feasible in selected patients who cannot tolerate a contrast agent.
Park
S M
SM
Department of Diagnostic Radiology, Ajou University School of Medicine, Suwon, Korea.
Kim
H S
HS
Jahng
G-H
GH
Ryu
C-W
CW
Kim
S Y
SY
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000473:pathology; D003287:Contrast Media; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods; D005240:Feasibility Studies; D005260:Female; D005910:Glioma / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D055815:Young Adult
D003287:Contrast Media
AJNR Am J Neuroradiol. 2004 May;25(5):746-55
15140713
Neuroradiology. 2008 Jan;50(1):9-16
17876570
Neuroradiology. 1997 Jul;39(7):483-9
9258924
AJNR Am J Neuroradiol. 2007 Aug;28(7):1280-6
17698528
Radiology. 2002 Apr;223(1):11-29
11930044
J Magn Reson Imaging. 2005 Oct;22(4):439-50
16163700
J Magn Reson Imaging. 2006 Jul;24(1):41-51
16755540
Magn Reson Med. 2004 Sep;52(3):612-8
15334582
AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21
14970020
Lancet. 2003 Jan 25;361(9354):323-31
12559880
AJNR Am J Neuroradiol. 2005 Apr;26(4):736-42
15814914
Ann Pathol. 2000 Oct;20(5):413-28
11084409
Radiology. 1997 Jul;204(1):272-7
9205259
Invest Radiol. 2003 Jul;38(7):409-14
12821854
J Magn Reson Imaging. 1999 Jan;9(1):53-60
10030650
Radiology. 1984 Feb;150(2):435-40
6691098
Neuroradiology. 2002 May;44(5):371-81
12012120
J Magn Reson Imaging. 2001 Apr;13(4):496-520
11276094
AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98
14625221
Rofo. 2005 Aug;177(8):1065-9
16021537
Radiology. 2005 Jun;235(3):985-91
15833979